Want to see IN:IPCALAB full AI Analyst Report?
IPCALAB Stock Chart & Stats
₹1762.70
₹14.90(0.85%)
At close: 4:00 PM EDT
₹1762.70
₹14.90(0.85%)
Day’s Range― - ―
52-Week Range₹1,252.95 - ₹1,941.40
Previous CloseN/A
Volume119.64K
Average Volume (3M)6.78K
Market Cap
₹443.18B
Enterprise Value₹417.40K
Total Cash (Recent Filing)₹11.98B
Total Debt (Recent Filing)₹8.09B
Price to Earnings (P/E)38.9
Beta0.18
Next Earnings
Aug 13, 2026EPS Estimate
12.16Next Dividend Ex-DateN/A
Dividend Yield0.23%
Share Statistics
EPS (TTM)44.98
Shares Outstanding253,659,230
10 Day Avg. Volume6,645
30 Day Avg. Volume6,776
Financial Highlights & Ratios
PEG Ratio0.65
Price to Book (P/B)5.04
Price to Sales (P/S)4.21
P/FCF Ratio83.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)55.29
Revenue Forecast (FY)₹107.74B
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthVery low leverage provides durable financial flexibility: it cushions the business against revenue/margin cycles, supports continued regulatory compliance investments, funds capex or targeted M&A, and reduces refinancing risk, all of which strengthen long-term resilience.
Diversified API + FDF ModelOperating both APIs and finished dosages creates vertical integration benefits: captive API use can lift gross margins, while sales across branded domestic and international generic channels reduce single-market exposure and support stable revenue mix over time.
Positive Cash GenerationConsistent positive operating and free cash flow, with a rebound in 2026, underpins the company's ability to fund R&D, maintain plants for regulatory compliance, invest in capacity, and service stakeholders without relying on high leverage, supporting long-term operations.
Bears Say
Margin Compression & Slower GrowthA durable slowdown to low single-digit top-line growth combined with meaningful margin erosion indicates structural pressure from pricing, cost inflation, or mix shifts. Sustained margin decline can erode reinvestment capacity and reduce long-term earnings power.
Weak Cash ConversionFree cash flow converting at under half of reported net income signals working-capital or capex absorption of earnings. Persistently weak conversion limits discretionary financing for growth, dividends, or deleveraging and raises sensitivity to operational setbacks.
Declining Capital EfficiencyA decline from earlier ROE levels implies falling capital efficiency driven by weaker margins or higher asset intensity. If sustained, lower ROE reduces shareholder returns and may require higher reinvestment to deliver comparable growth, pressuring long-term value creation.
IPCA Laboratories Limited News
IPCALAB FAQ
What was IPCA Laboratories Limited’s price range in the past 12 months?
IPCA Laboratories Limited lowest stock price was ₹1252.95 and its highest was ₹1941.40 in the past 12 months.
What is IPCA Laboratories Limited’s market cap?
IPCA Laboratories Limited’s market cap is ₹443.18B.
When is IPCA Laboratories Limited’s upcoming earnings report date?
IPCA Laboratories Limited’s upcoming earnings report date is Aug 13, 2026 which is in 6 days.
How were IPCA Laboratories Limited’s earnings last quarter?
IPCA Laboratories Limited released its earnings results on May 29, 2026. The company reported ₹11.8 earnings per share for the quarter, beating the consensus estimate of ₹10.074 by ₹1.726.
Is IPCA Laboratories Limited overvalued?
According to Wall Street analysts IPCA Laboratories Limited’s price is currently Overvalued.
Does IPCA Laboratories Limited pay dividends?
IPCA Laboratories Limited pays a Annually dividend of ₹6 which represents an annual dividend yield of 0.23%. See more information on IPCA Laboratories Limited dividends here
What is IPCA Laboratories Limited’s EPS estimate?
IPCA Laboratories Limited’s EPS estimate is 12.16.
How many shares outstanding does IPCA Laboratories Limited have?
IPCA Laboratories Limited has 253,659,230 shares outstanding.
What happened to IPCA Laboratories Limited’s price movement after its last earnings report?
IPCA Laboratories Limited reported an EPS of ₹11.8 in its last earnings report, beating expectations of ₹10.074. Following the earnings report the stock price went down -3.753%.
Which hedge fund is a major shareholder of IPCA Laboratories Limited?
Currently, no hedge funds are holding shares in IN:IPCALAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
IPCA Laboratories Limited
Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, the Commonwealth of Independent States, and Australasia. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, anti-hypertensive, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. The company also exports its products worldwide. Ipca Laboratories Limited was incorporated in 1949 and is based in Mumbai, India.
Technical Analysis
Ajanta Pharma Limited
―
Emcure Pharmaceuticals Limited
―
―
Neuland Laboratories Ltd.
―
Wockhardt Limited
―